IMSL Integrated Master Securities Pvt Ltd

Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Lenalidomide Capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg.

Lenalidomide Capsules are bioequivalent to Revlimid' Capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg, of Bristol-Myers Squibb Company. This product will be manufactured at Lupin's Pithampur facility in India.

Lenalidomide Capsules are indicated for the treatment of adult patients with:

 -Multiple myeloma (MM), in combination with dexamethasone
 - MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)
 - Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.

Lenalidomide Capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg (RLD Revlimid') had estimated annual sales of USD 7,511 million in the U.S. (IQVIA MAT July 2025).

Powered by Capital Market - Live News

IMSL APPS

Company

Market Board

Important Links

Authorised Person Details
Branch Details
Account Opening Process
Investor Complaints Redressal Process
Online Grievance Redressal (ODR)
SEBI SCORES 2.0
Voluntary Freezing/Blocking Policy
Client Collateral Segregation & Monitoring
Online Account Closure
Vernacular Client Registration Documents -
Equity | Commodity

KRA Status and Validation

Contact

	303, New Delhi House, 27, Barakhamba Road, New Delhi-110001. CIN No. U74899DL1995PTC070418
	011-43074307-30 \| Fax: 011-43074315
Compliance Officers: Mr. Pravin Kumar Sinha (NSE, BSE & MCX)
	011-43074317
	compliance@integratedmaster.com
Mr. Gopal Singh Kathayat (CDSL & NSDL)
	011-43074310
	dp@integratedmaster.com
	Investor Grievance (IG): suggestions@integratedmaster.com

"We also do Pro trading in Commodity/Equity/Equity Derivatives/CDS Segment"

Risk Disclosure on Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on "Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment", wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

ATTENTION INVESTORS

The Stock Exchange, Mumbai is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time.
The Stock Exchange, Mumbai is not answerable, responsible or liable for any information on this Website or for any services rendered by our employees, our servants, and us.

ATTENTION INVESTORS

URGENT !!

All clients are requested to update below 6 mandatory KYC at-tributes before 31st March, 2022 to avoid blocking of Trading Account and freezing of Demat Account

NAME
MOBILE NUMBER
COMPLETE ADDRESS (including Pin code if resident of India)
VALID EMAIL ID
PAN NUMBER
INCOME DETAILS

UPDATE NOW!

ATTENTION INVESTORS

URGENT !!

All clients are requested to ensure that their PAN Numbers are mapped with the Aadhar card for seamless Trading. As per Circular Ref No: NSE/ISC/49477 clients who do not have their PAN linked with Aadhar won't be able to trade post September 30,2021.

Know More

Integrated Master Securities Pvt Ltd: Member of NSE & BSE- SEBI Registration No-INZ000175931 | CDSL: Depository Services through Integrated Master Securities Pvt Ltd- SEBI Registration No: IN-DP-CDSL-97-2000 | NDSL: Depository Services through Integrated Master Securities Pvt Ltd- SEBI Registration No: IN-DP-499-2020 | MCX - SEBI Registration No-INZ000175931

Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market are subject to market risk, read all the related documents carefully before investing.

ATTENTION INVESTORS:
1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w. e. f. September 01, 2020.
2. Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month
4. Prevent Unauthorized Transactions in your demat account. Update your Mobile Number / Email ID with Integrated Master Securities Pvt. Ltd. To receive alerts on your Registered Mobile for all debit and other important transactions in your demat account and information of your transactions directly from NSDL\CDSL on the same day. Issued in the interest of investors.
5. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.

Designed, Developed and Powered By CMOTS Infotech ( ISO 9001:2015 Certified )

DJIA 45773.62
130.84 -0.29%

S&P 500 6626.82
-9.46 -0.14%

HANG SENG 26908.40
469.88 1.78%

NIKKEI 225 44831.00
-71.27 -0.16%

FTSE 100 9208.37
12.71 0.14%

NIFTY 25330.25
91.15 0.36%

× Ask Your Question